There are 2789 resources available
452P - Predicting response to bevacizumab in colorectal cancer by integrating radiomics to clinical and genomic features
Presenter: Gianluca Milanese
Session: ePoster Display
453P - Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre
Presenter: David Lau
Session: ePoster Display
454P - CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value
Presenter: Francesca Battaglin
Session: ePoster Display
455P - Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Presenter: Manuel Valladares-Ayerbes
Session: ePoster Display
511TiP - A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
Presenter: Dongsheng Zhang
Session: ePoster Display
521P - Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Presenter: Maria Vieito
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display